Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2231-pub
Abstract: Background: Despite multiple therapeutic options for people with T2DM, 48% of people do not achieve Hemoglobin A1c (HbA1c) goal. GLP-1 receptor agonists may be beneficial to patients with T2DM who are on large insulin doses… read more here.
Keywords: insulin; total daily; glp; daily insulin ... See more keywords
Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-5-lb
Abstract: In most patients with T1D, adequate glycemic control is not achieved with insulin therapy alone, and intensifying insulin therapy can increase the risk of hypoglycemia. Sotagliflozin (SOTA) is a dual SGLT1 and SGLT2 inhibitor, which… read more here.
Keywords: insulin; sanofi; insulin therapy; self ... See more keywords